952616-39-6 Usage
Description
(+/-)-cis-3-(Carbobenzoxyamino)cyclohexanecarboxylic Acid, also known as Carbobenzyloxy-L-proline, is a chemical compound with the molecular formula C16H19NO4. It is a derivative of proline and is commonly used in organic chemistry as a chiral auxiliary for the asymmetric synthesis of amino acids and other biologically active compounds. It has a cyclohexane ring and a carboxylic acid moiety, making it useful for forming peptide bonds. Additionally, it has been studied for its potential pharmacological properties, including anti-inflammatory and analgesic effects. Overall, (+/-)-cis-3-(Carbobenzoxyamino)cyclohexanecarboxylic Acid is a versatile compound with applications in both organic synthesis and potential therapeutic uses.
Uses
Used in Organic Synthesis:
(+/-)-cis-3-(Carbobenzoxyamino)cyclohexanecarboxylic Acid is used as a chiral auxiliary for the asymmetric synthesis of amino acids and other biologically active compounds. Its cyclohexane ring and carboxylic acid moiety make it useful for forming peptide bonds, which is essential in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
(+/-)-cis-3-(Carbobenzoxyamino)cyclohexanecarboxylic Acid is used as a potential therapeutic agent for its anti-inflammatory and analgesic effects. Its pharmacological properties are being studied for the development of new drugs to treat various conditions, such as pain and inflammation.
Check Digit Verification of cas no
The CAS Registry Mumber 952616-39-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,6,1 and 6 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 952616-39:
(8*9)+(7*5)+(6*2)+(5*6)+(4*1)+(3*6)+(2*3)+(1*9)=186
186 % 10 = 6
So 952616-39-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H19NO4/c17-14(18)12-7-4-8-13(9-12)16-15(19)20-10-11-5-2-1-3-6-11/h1-3,5-6,12-13H,4,7-10H2,(H,16,19)(H,17,18)
952616-39-6Relevant articles and documents
FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
Page/Page column 248; 262, (2022/04/03)
Provided are compounds according to any of Formula (I-1) to (I-7), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. Methods for preparing compounds according to any of Formula (I-1) to (I-7) are also provided.
Inhibitors of influenza viruses replication
-
, (2016/06/14)
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
INHIBITORS OF INFLUENZA VIRUSES REPLICATION
-
, (2014/01/08)
Compound according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. Uses of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient.
